10-K: VYNE Therapeutics Pivots to Graves Disease via Yarrow Merger

VYNE Therapeutics announced a definitive merger agreement with Yarrow Biosciences, shifting its strategic focus to Yarrow's clinical-stage TSHR antibody for Graves Disease, following setbacks in its BET inhibitor programs.

Summary

• VYNE Therapeutics entered into an Agreement and Plan of Merger and Reorganization with Yarrow Biosciences, Inc. on December 17, 2025, amended on January 30, 2026.
• Post-merger, VYNE will change its name to Yarrow Bioscience, Inc., and the Combined Company will focus on advancing YB-101 (GS-098) for Graves Disease and Thyroid Eye Disease.
• Pre-Merger VYNE stockholders are expected to own approximately 3% of the Combined Company, while pre-Merger Yarrow stockholders (including financing investors) are expected to own approximately 97%.
• A special cash dividend of approximately $14.5 million to $16.5 million in aggregate is expected to be declared for pre-Merger VYNE stockholders and warrant holders.
• The Phase 2b trial for repibresib gel (VYN201) in nonsegmental vitiligo failed to meet its primary endpoint (F-VASI50 at week 24) and a key secondary endpoint (F-VASI75) in July 2025, leading to its termination.
• The Phase 1b trial for VYN202 in moderate-to-severe plaque psoriasis was placed on clinical hold by the FDA in April 2025 due to observed testicular toxicity in dogs from a non-clinical toxicology study.
• The FDA lifted the clinical hold for VYN202 for female subjects at 0.25 mg and 0.5 mg doses in June 2025, but required a 12-week non-clinical toxicology study in dogs to resume studies in male subjects.
• Despite interim unblinded clinical data showing improvements in VYN202-treated subjects (n=6) compared to placebo (n=1), the Phase 1b psoriasis trial was terminated in July 2025 to advance VYN202 into other serious immune-mediated diseases.
• A repeat non-clinical toxicology study of VYN202 in male dogs was initiated in October 2025, with completion expected in the second half of 2026 and a final report in the fourth quarter of 2026.
• Net loss for the year ended December 31, 2025, was $26.5 million, a decrease from $39.8 million in 2024.
• Research and development expenses decreased by $11.7 million (37.8%) to $19.2 million in 2025, primarily due to the termination of the repibresib trial and reduced VYN202 clinical expenses.
• General and administrative expenses decreased by $2.1 million (16.0%) to $11.1 million in 2025.
• Cash, cash equivalents, and marketable securities totaled $29.0 million as of December 31, 2025.
• The company received a Nasdaq notice on September 11, 2025, for non-compliance with the minimum bid price requirement ($1.00), with a compliance deadline of March 10, 2026.
• The company operates on a fully remote model since November 1, 2025, after its Bridgewater, New Jersey office lease expired.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development for VYNE's existing pipeline, with the failure of repibresib and the clinical hold/termination of VYN202's psoriasis trial. The merger with Yarrow represents a pivot, but existing shareholders face substantial dilution and the success of the new pipeline is uncertain.

Positives

• The definitive merger agreement with Yarrow Biosciences provides a new strategic direction and pipeline asset (YB-101) for Graves Disease and Thyroid Eye Disease.
• Yarrow Biosciences secured $100.0 million in Series A Preferred Stock financing and an additional $100.0 million commitment in a Pre-Closing Financing, strengthening the combined entity's capital position.
• Interim unblinded clinical data from the VYN202 Phase 1b trial showed improvements in signs and symptoms of disease and reductions in serum cytokine levels in treated subjects.
• The FDA lifted the clinical hold for VYN202 for female subjects at two doses (0.25 mg and 0.5 mg).
• Net loss decreased to $26.5 million in 2025 from $39.8 million in 2024, indicating improved financial performance.
• Research and development expenses decreased by 37.8% in 2025, reflecting cost reduction efforts.
• The company recognized $1.3 million in income during 2025 related to the closure of the IRS examination period of its ERTC filings.

Negatives

• The repibresib gel Phase 2b trial in nonsegmental vitiligo failed to meet its primary and key secondary endpoints, leading to its termination.
• The VYN202 Phase 1b trial was placed on clinical hold by the FDA due to observed testicular toxicity in dogs, requiring further non-clinical studies for male subjects and leading to the trial's termination for psoriasis.
• Pre-Merger VYNE stockholders are expected to experience significant ownership dilution, owning approximately 3% of the Combined Company.
• The company received a Nasdaq non-compliance notice for its minimum bid price requirement, risking delisting if compliance is not regained by March 10, 2026.
• An accumulated deficit of $757.7 million as of December 31, 2025, highlights historical losses.
• Reliance on third-party manufacturers, particularly WuXi Apptec in China, exposes the company to potential trade restrictions and supply chain disruptions under the BIOSECURE Act.
• The company is subject to 'baby shelf rules' limiting capital raises via Form S-3 to one-third of its public float, which is currently below $75.0 million.

Risks

• Failure to complete, or delays in completing, the potential Merger with Yarrow could materially and adversely affect results of operations, business, financial results, and/or common stock price.
• The issuance of common stock to Yarrow stockholders and the resulting change in control from the Merger must be approved by stockholders.
• If the Merger is not completed, the stock price may decline significantly.
• Some of Yarrow's and VYNE's directors and executive officers have interests in the Merger that are different from stockholders.
• If the Merger or another strategic transaction is not successfully consummated, the board of directors may decide to pursue a dissolution and liquidation of VYNE, with uncertain cash distribution to stockholders.
• The reverse stock split may not increase the Combined Company's stock price over the long-term or improve liquidity.
• Limited history as a clinical-stage biopharmaceutical company developing product candidates for immuno-inflammatory conditions may make it difficult to assess future viability.
• Business is substantially dependent on the successful development of BET inhibitor product candidates (if Merger is not consummated).
• Delays in enrolling patients and successfully completing clinical trials for product candidates, or being delayed in, or prevented from, commencing such trials due to factors largely beyond control.
• Clinical drug development is very expensive, time-consuming, and uncertain; preclinical studies and clinical trials may fail to adequately demonstrate safety and efficacy.
• New chemical entities may require more time and resources for development, testing, and regulatory approval.
• Results obtained in preclinical studies and completed clinical trials may not predict success in later clinical trials.
• Top-line and preliminary data from clinical trials may change as additional data become available and are subject to audit and verification procedures.
• Limited resources may be spent to pursue a particular product candidate or indication and fail to capitalize on more profitable ones.
• Failure to obtain regulatory approvals to market product candidates, or delays in obtaining such approvals.
• Failure to successfully in-license, acquire, develop, and market additional product candidates or approved products could impair business growth.
• Decision not to continue developing any product candidates at any time during development or after approval would reduce or eliminate potential return on investment.
• Subject to various U.S. federal, state, local, and foreign health care fraud and abuse laws; violations could result in substantial penalties.
• Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly to obtain regulatory approval and to produce, market, and distribute products.
• Various risks and uncertainties arising out of the completed divestiture of the commercial business, including retained liabilities and no diligence obligations for sales milestones.
• The trading price of the shares of common stock is volatile, and stockholders could incur substantial losses.
• Need for substantial additional funding to pursue business objectives if the Merger is not completed; inability to raise capital could curtail planned operations.
• Significant losses incurred since inception and anticipated to continue for the foreseeable future.
• SEC regulations limit the amount of funds that can be raised during any 12-month period pursuant to a shelf registration statement on Form S-3 ('baby shelf rules').
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing proprietary rights.
• Collaboration arrangements that may be entered into in the future may not be successful.
• Supply interruptions may disrupt the availability of product candidates and cause delays in conducting preclinical or clinical activities, particularly due to reliance on a primary API manufacturer in China (WuXi Apptec) and potential impact of the BIOSECURE Act.
• May not be able to utilize a significant portion of net operating loss carryforwards and research and development tax credit carryforwards due to ownership changes (Section 382).
• The Israeli Tax Authority may disagree with conclusions regarding certain tax positions, resulting in unanticipated costs or taxes.
• Failure to attract and keep senior management and key scientific personnel.
• May become subject to lawsuits or investigations that could have a material adverse impact on business.
• Information technology systems or those of third parties upon which the company relies, or data, could be compromised, leading to adverse consequences.
• Employees, independent contractors, principal investigators, consultants, vendors, CROs, and partners may engage in misconduct or other improper activities.
• Unfavorable global economic conditions could adversely affect business, financial condition, or results of operations.
• Subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, and industry standards related to data privacy and security.
• Use of generative artificial intelligence, agentic artificial intelligence, automated decision-making tools, or other AI technologies may lead to various laws and regulations, compliance costs, and increased risks.
• Changes in U.S. or foreign patent law and practice could diminish the value of patents.
• Infringement or alleged infringement or other violation of intellectual property rights of third parties could harm the business.
• Inability to enforce covenants not to compete under applicable employment laws.
• Provisions in corporate charter documents and under Delaware law may prevent or frustrate attempts by stockholders to change management and hinder efforts to acquire a controlling interest.
• Claims for indemnification by directors and officers may reduce available funds.
• Exclusive forum selection clauses could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• An active public market for common stock may not be sustained.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the company, stock price and trading volume could decline.
• Sales of a substantial number of shares of common stock by existing stockholders in the public market could cause the stock price to fall.
• No current intention to pay dividends on common stock (except for the potential special merger dividend).
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate financial statements on a timely basis.
• Significant costs and demands upon management as a result of being a public company.
• Not currently in compliance with the continued listing requirements for the Nasdaq Capital Market.
• Subject to risks related to climate change in the long term and increasing sensitivity to environmental, social, and governance (ESG) matters.

Future Outlook

The Combined Company plans to focus on advancing YB-101 (GS-098), a clinical-stage TSHR antibody, for the treatment of Graves Disease and explore a clinical development plan for Thyroid Eye Disease. VYNE may continue to evaluate opportunities for its existing product candidates, repibresib and VYN202, which could include a sale, license, transfer, disposition, divestiture, or other monetization transaction to a third party or related party, provided it does not result in material post-closing obligations without Yarrow's consent. If the Merger Agreement is terminated, VYNE may pursue other strategic alternatives, including financing opportunities or liquidation. The repeat non-clinical toxicology study of VYN202 in male dogs is expected to be completed in the second half of 2026, with a final report anticipated in the fourth quarter of 2026.

Management Comments

• VYNE management evaluated opportunities for repibresib and VYN202, including as part of broader strategic alternatives.
• VYNE also implemented cost reductions to extend its cash runway.
• Following the strategic review, on December 17, 2025, VYNE entered into a Merger Agreement with Yarrow and Merger Sub, pursuant to which, among other matters, VYNE would merge with Yarrow to advance Yarrow's TSHR antibody YB-101.
• The Compensation Committee determined not to award any performance bonuses to Mr. Domzalski, Mr. Stuart and Ms. Harsch in respect of 2025.
• The Compensation Committee approved a cash retention payment for each of our four executive employees to incentivize them to remain with the Company through the completion of the covenants and closing conditions in the Merger Agreement.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is highly competitive, with many large pharmaceutical and biotechnology companies developing treatments for immune-mediated conditions. The pivot to YB-101 for Graves Disease positions the combined entity in a specific niche, but it will still face competition from established players and emerging therapies. The ongoing regulatory scrutiny over drug pricing and the impact of legislation like the IRA and OBBBA highlight a challenging environment for pharmaceutical profitability, potentially affecting the combined company's future revenue streams. The reliance on Chinese API manufacturers like WuXi Apptec also exposes the company to geopolitical risks and potential supply chain disruptions, a growing concern across the industry.

Comparison to Industry Standards

• The psoriasis market is highly competitive, with approved anti-IL-17 antibody therapies including COSENTYX (Novartis), TALTZ (Eli Lilly), SILIQ (Bausch Health), and BIMZELX (UCB SA).
• Other classes of injectable biologics approved for use in indications for which IL-17 therapeutics are also approved include anti-IL-12/23 and anti-TNF monoclonal antibodies marketed by AbbVie, Sun Pharmaceutical Industries, and Janssen Pharmaceuticals.
• The oral PDE4 inhibitor, OTEZLA (Amgen), and oral TYK2 inhibitor, SOTYKTU (Bristol Myers Squibb), are approved for the treatment of psoriasis.
• Other oral therapeutic candidates, including TYK2 inhibitors, oral IL-17 inhibitors, and oral IL-23 inhibitors, are being developed by Takeda Pharmaceutical Company, Ventyx Biosciences, Eli Lilly, LEO Pharma, and Johnson & Johnson.
• VYNE's BET inhibitor platform aims to differentiate by maximizing BD2 selectivity to alleviate toxicities (gastrointestinal toxicity and bone marrow suppressive effects like thrombocytopenia) observed by other less BD2-selective BET inhibitors in development for oncology.

Management Changes

Corporate Governance

Legal Proceedings

• There are currently no claims or actions pending against the company that, in the opinion of management, are likely to have a material adverse effect on the business.

Related Party Transactions

• Employment agreements with executive officers (David Domzalski, Iain Stuart, Mutya Harsch) detailing base salary, bonus eligibility, and severance terms.
• Indemnification agreements with each director and executive officer, requiring the company to indemnify them to the fullest extent permitted by Delaware law.
• The Yarrow Series A Preferred Stock Financing and the Yarrow Pre-Closing Financing involved certain institutional investors led by an affiliate of RTW Investments, who will become significant shareholders of the Combined Company post-merger.

Stakeholder Impact

• Shareholders (pre-Merger VYNE): Face significant ownership dilution (expected to own ~3% of Combined Company), but will receive a special cash dividend of $14.5 million to $16.5 million. They also bear the risk of Nasdaq delisting if compliance is not regained and the uncertainty of the new pipeline's success.
• Shareholders (Yarrow): Will become the majority owners (~97%) of the Combined Company, benefiting from the $200 million in new financing and the advancement of YB-101.
• Employees: May experience increased attrition, challenges in recruiting, and distraction during the merger integration process. Executive employees have been offered cash retention payments to incentivize their continued service.
• Customers/Patients: The termination of the repibresib gel trial means no new treatment for nonsegmental vitiligo from this program. The VYN202 development for psoriasis is halted, with future focus on other immune-mediated diseases, potentially delaying access to this therapy. The new focus on YB-101 offers potential future treatments for Graves Disease and Thyroid Eye Disease.
• Suppliers/Contract Manufacturers: Continued reliance on third-party manufacturers, particularly WuXi Apptec in China, exposes them to potential trade restrictions (e.g., BIOSECURE Act) and supply chain disruptions, which could impact their business with the company.
• Creditors: The company has no outstanding debt as of December 31, 2025. However, if the Merger fails and no other strategic transaction is found, the risk of liquidation could impact potential future creditors.

Next Steps

• Complete the Merger with Yarrow Biosciences, Inc., anticipated in the second quarter of 2026.
• Focus on advancing YB-101 for Graves Disease and exploring a clinical development plan for Thyroid Eye Disease.
• Continue to evaluate opportunities for repibresib and VYN202, which may include a sale, license, transfer, disposition, divestiture, or other monetization transaction.
• Complete the repeat non-clinical toxicology study of VYN202 in male dogs (expected H2 2026, final report Q4 2026).
• Regain compliance with Nasdaq minimum bid price requirement by March 10, 2026.
• If the Merger Agreement is terminated, pursue other strategic alternatives, including financing opportunities or liquidation.

Key Dates

Recommendation

The filing reveals significant setbacks for VYNE's existing pipeline, with the lead product repibresib failing its Phase 2b trial and VYN202's Phase 1b trial being terminated due to a clinical hold. While the merger with Yarrow Biosciences offers a new strategic direction, it comes with substantial dilution for current VYNE shareholders (expected to own only 3% of the combined entity). The company also faces Nasdaq delisting risk and ongoing funding challenges if the merger fails. These factors indicate a high level of uncertainty and a significant negative shift for existing VYNE investors.

Keywords

Biopharmaceutical, Merger, Yarrow Biosciences, Graves Disease, Thyroid Eye Disease, YB-101, BET inhibitor, VYN202, Repibresib, Clinical Trial, FDA Clinical Hold, Vitiligo, Psoriasis, Nasdaq Delisting, Capital Raise, SEC Filing, 10-K, Drug Development, Immuno-inflammatory conditions, Epigenetic Regulators, NF-kB pathway, Intellectual Property, Corporate Governance, Financial Performance, Liquidity, Risk Management